Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42,088 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study.
Yang Z, Li J, Hu Y, Chen M, Peng D, Zong D, Shang Q, Tao L, Zhao Y, Ni Y, Ye J, Xie Y, Yang L, Lin Q, Cai C, Xu N, Huang X, Dong X, Zhou Z, Yu Y, Shangguan Z, Xu Y, Ying W, Weng M, Yuan Z, Dong Z, Li J, Zheng Z, Pan J, Liu L, Ye J, Zhang Z, Li W, Zhu J, Jin S, Li Y, Ding C. Yang Z, et al. Among authors: zhu j. Target Oncol. 2019 Dec;14(6):719-728. doi: 10.1007/s11523-019-00682-0. Target Oncol. 2019. PMID: 31691892
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.
Zhou HQ, Zhang YX, Chen G, Yu QT, Zhang H, Wu GW, Wu D, Lin YC, Zhu JF, Chen JH, Hu XH, Lan B, Zhou ZQ, Lin HF, Wang ZB, Lei XL, Pan SM, Chen LM, Zhang J, Kong TD, Yao JC, Zheng X, Li F, Zhang L, Fang WF. Zhou HQ, et al. Among authors: zhu jf. Signal Transduct Target Ther. 2024 Aug 13;9(1):215. doi: 10.1038/s41392-024-01927-9. Signal Transduct Target Ther. 2024. PMID: 39134529 Free PMC article. Clinical Trial.
Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.
Shao Y, Zhang J, Feng Z, Wu W, Zhao X, Zhu M, Xiao Y, Pang J, Zhu J, Qu H, Yuan M, Xia G, Liu M, Li H. Shao Y, et al. Among authors: zhu j, zhu m. Cancer Sci. 2024 Aug;115(8):2751-2761. doi: 10.1111/cas.16250. Epub 2024 Jun 26. Cancer Sci. 2024. PMID: 38932450 Free PMC article.
42,088 results
You have reached the last available page of results. Please see the User Guide for more information.